Different effects of crizotinib treatment in two non-small cell lung cancer patients with SDC4::ROS1 fusion variants

Yuta Ohishi, Yoko Nakanishi, Yukari Hirotani, Atsuko Suzuki, Tomoyuki Tanino, Haruna Nishimaki-Watanabe, Hiroko Kobayashi, Fumi Nozaki, Sumie Ohni, Xiaoyan Tang, Kentaro Hayashi, Yoshiko Nakagawa, Tetsuo Shimizu, Ichiro Tsujino, Noriaki Takahashi, Yasuhiro Gon, Shinobu Masuda

研究成果: ジャーナルへの寄稿記事査読

1 被引用数 (Scopus)


The possibility of stratifying patients according to differences in ROS proto-oncogene 1 (ROS1) fusion partners has been discussed. This study aimed to clarify the clinicopathological differences between two SDC4::ROS1 positive NSCLC cases who had different responses to crizotinib. Cytology and pathology samples from two NSCLC cases with SDC4::ROS1 who were diagnosed and treated with crizotinib at Nihon University Itabashi Hospital were obtained. Case 1 has been well-controlled with crizotinib for over 5 years, but case 2 was worse and overall survival was 19 months. Sequencing analysis of ROS1 fusion genes was performed by reverse-transcription-PCR and Sanger's sequencing methods. In addition, thyroid transcription factor (TTF)-1, ROS-1, Ki67, and phosphorylated extracellular signal-regulated kinase (pERK)1/2 expression were investigated using immunohistochemistry. Sequencing analysis showed SDC4 exon2::ROS1 exon 32 (exon33 deleted) in case 1, and coexistence of SDC4 exon2::ROS1 exon 34 and SDC4 exon2::ROS1 exon35 in case 2. The Ki67 index was not different, but ROS1 and pERK1/2 expression levels tended to be higher in the tumor cells of case 2 than in case 1. Therapeutic response to crizotinib and patients' prognosis in ROS1 rearranged NSCLC may be related to the activation of ROS1 signaling, depending on ROS1 and pERK1/2 overexpression status, even if the ROS1 fusion partner is the same.

ジャーナルThoracic Cancer
出版ステータス出版済み - 1月 2024


「Different effects of crizotinib treatment in two non-small cell lung cancer patients with SDC4::ROS1 fusion variants」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。